Country: United Kingdom
Bahasa: Inggeris
Sumber: VMD (Veterinary Medicines Directorate)
Chlamydophila felis, Feline calicivirus, Feline panleukopenia virus, Feline viral rhinotracheitis virus
Intervet International BV
QI06AF01
Chlamydophila felis, Feline calicivirus, Feline panleukopenia virus, Feline viral rhinotracheitis virus
Expired
Revised: June 2011 AN: 00364/2010 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Nobivac Forcat (AT/DE: Nobivac RCP-Chlam) 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Per dose of 1 ml: Lyophilisate: ACTIVE SUBSTANCES: live attenuated feline calicivirus, strain F9: 4.6 log 10 PFU 1 ; live attenuated feline herpes virus type 1, strain G2620A: 5.2 log 10 PFU 1 ; live attenuated feline panleucopenia virus, strain MW-1: 4.3 log 10 CCID 50 2 ; live attenuated _Chlamydophila felis_, strain Baker: 2.3 log 10 CCID 50 2 . 1 PFU: Plaque-Forming Units 2 CCID 50 : Cell Culture Infective Dosis 50% EXCIPIENTS: For a full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Lyophilisate and solvent for suspension for injection. 4. CLINICAL PARTICULARS 4.1 TARGET SPECIES Cats 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES Active immunisation of cats: to reduce the clinical signs caused by infection with feline calicivirus and feline herpes virus type 1, to reduce the severity of the clinical signs caused by infection with _Chlamydophila felis_, to prevent the clinical signs, leucopenia and virus excretion caused by infection with feline panleucopenia virus. Onset of immunity: for FCV and FHV: 4 weeks; for FPLV and _C. felis_: 3 weeks. Duration of immunity for FCV, FHV, _C. felis_: 1 year, for FPLV: 3 years. 4.3 CONTRAINDICATIONS See section 4.7 Page 1 of 5 Revised: June 2011 AN: 00364/2010 4.4 SPECIAL WARNINGS Because antimicrobials may inactivate the live _C. felis_ vaccine strain, systemic antimicrobial therapy should be avoided during vaccination and for a two week period afterwards. Maternal antibodies, which may persist up to the age of 9-12 weeks, can have a negative influence on the efficacy of vaccination. In the presence of maternal antibodies, vaccination may not completely prevent the clinical signs, leucopenia and virus excretion following an FPLV infection, and may reduce the protection against a _C. felis_ infection. In such c Baca dokumen lengkap